Search

Your search keyword '"Fredy Orlando Guevara Pulido"' showing total 5 results
Start Over Author "Fredy Orlando Guevara Pulido"
5 results on '"Fredy Orlando Guevara Pulido"'

1. Volver a empezar: cirugía electiva durante la pandemia del SARS-CoV2. Recomendaciones desde la Asociación Colombiana de Cirugía

Author

Arnold Barrios Parra, Robín Germán Prieto Ortiz, Lilian Torregrosa Almonacid, Carlos Alberto Álvarez Tamayo, Juan David Hernández-Restrepo, Luis Gabriel González Higuera, Álvaro Valencia Ceballos, Jorge Ospina Ospina Londoño, Jorge Augusto Herrera Chaparro, John Henry Moore Perea, Juan Carlos Ayala Acosta, Nayib Zurita Medrano, Felipe Enrique Vargas Barato, Hernando José Coba Barrios, Roosevelt Fajardo Gómez, Bernardo Alfonso Borraez Segura, Manuel Eduardo Moros Vera, Fredy Orlando Mendivelso Duarte, Olga Lucia Aristizabal, Fredy Orlando Guevara Pulido, Luis Felipe Cabrera-Vargas, and Patrizio Petrone

Subjects
COVID-19, virus SARS-CoV2, coronavirus, infecciones por coronavirus, pandemia, cirugía general, Surgery, RD1-811
Abstract

La pandemia por el virus SARS-CoV-2 y la enfermedad generada (COVID-19, del inglés Coronavirus 2019 Disease), llevó a nivel mundial a cambios significativos en la forma de prestar los servicios de salud, incluida la actividad quirúrgica. Como parte de esta realidad, se recomendó en Colombia la adopción de disposiciones enfocadas a preparar nuestro sistema de salud para enfrentar una avalancha de pacientes COVID-19, que se esperaba fuera similar a la presentada en otros países. Las medidas se tomaron en el momento oportuno, ganando tiempo de preparación, sin que hasta la fecha (8 semanas después del primer caso diagnosticado en Colombia) se haya desbordado la demanda de atención, modificando la forma esperada de la curva epidemiológica, con un número menor de pacientes.

Published
2020
Full Text
View/download PDF

2. Citomegalovirus diseminado: a propósito de un caso

Author

Gabriel Alonso Mosquera Klinger, Fredy Orlando Guevara Pulido, and Carlos Álvarez Moreno

Subjects
Medicine
Abstract

El artículo presenta el caso de un hombre sin antecedentes previos de enfermedad, que consultó inicialmente por dolor abdominal. Se documentó colecistitis aguda, en la patología con hallazgos de citomegalovirus; adicionalmente, presentaba múltiples manifestaciones: síntomas respiratorios, sangrado gastrointestinal y pancitopenia. Se documentó infección por VIH y muestras serológicas e histológicas de citomegalovirus. Se hace diagnóstico de citomegalovirus diseminado en el contexto de infección por VIH.

Published
2014

3. Volver a empezar: cirugía electiva durante la pandemia del SARS-CoV2. Recomendaciones desde la Asociación Colombiana de Cirugía

Author

Juan David Hernández-Restrepo, Hernando José Coba Barrios, John Henry Moore Perea, Roosevelt Fajardo Gómez, Manuel Eduardo Moros Vera, Jorge Augusto Herrera Chaparro, Nayib Zurita Medrano, Juan Carlos Ayala Acosta, Luis Gabriel González Higuera, Olga Lucia Aristizabal, Álvaro Valencia Ceballos, Carlos Alberto Álvarez Tamayo, Lilian Torregrosa Almonacid, Fredy Orlando Guevara Pulido, Arnold José Barrios Parra, Patrizio Petrone, Robin Germán Prieto Ortiz, Luis F. Cabrera-Vargas, Jorge Ospina Ospina Londoño, Bernardo A Borráez Segura, Fredy Orlando Mendivelso Duarte, and Felipe Enrique Vargas Barato

Subjects
RD1-811, coronavirus, infecciones por coronavirus, pandemia, COVID-19, cirugía general, Surgery, virus SARS-CoV2
Abstract

La pandemia por el virus SARS-CoV-2 y la enfermedad generada (COVID-19, del inglés Coronavirus 2019 Disease), llevó a nivel mundial a cambios significativos en la forma de prestar los servicios de salud, incluida la actividad quirúrgica. Como parte de esta realidad, se recomendó en Colombia la adopción de disposiciones enfocadas a preparar nuestro sistema de salud para enfrentar una avalancha de pacientes COVID-19, que se esperaba fuera similar a la presentada en otros países. Las medidas se tomaron en el momento oportuno, ganando tiempo de preparación, sin que hasta la fecha (8 semanas después del primer caso diagnosticado en Colombia) se haya desbordado la demanda de atención, modificando la forma esperada de la curva epidemiológica, con un número menor de pacientes.

Published
2020

4. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results

Author

Carlos Guijarro, Farid Zand, Mohamed solyman Kabil, Sven Trelle, Birgitte Tholin, Belén Comeche, Johan Alexander Azañero Haro, Gonzalo Sierra Torres, Quarraisha Abdool Karim, Kari Tikkinen, Jean-michel Molina, Atousa Hakamifard, George M Varghese, Oscar Josue Ponce Ponte, Mazin Barry, Pilar Vizcarra, Niccolo Riccardi, Natalia Pérez-Macias, Aynaa AlSharidi, Nelson Lee, Alexandra Binnie, Firouzé BANI-SADR, Beatriz Díaz-Pollán, Aldo Pietro Maggioni, Ilkka Kalliala, Florian Desgranges, Anders Benjamin Kildal, Katerina Nezvalova-Henriksen, Corinne Merle, Andrés Martín Alcántara, Benjamin Gaborit, Daniel Lozano Martín, Antonio Ramos-Martinez, Miguel Villegas-Chiroque, Fredy Orlando Guevara Pulido, Ana Fernández-Cruz, Cormac McCarthy, Thesla Palanee-Phillips, Annalisa Marinosci, Abdullah Assiri, Florent Wallet, Juan Pablo Balbuena, Avik Ray, Francesc Puchades, Rajarao Mesipogu, Marjatta Sinisalo, Jonathan Sterne, Antonio Portolés, Heike Cappel-Porter, Jussi Mustonen, Jeremy Nel, BRUNO MOURVILLIER, María Consuelo Miranda Montoya, Chiara Fanciulli, L Marjukka Myllärniemi, Edinson Dante Meregildo Rodriguez, Alexy Inciarte, Mohamed Hassany, François Danion, Elena Muñez Rubio, Jean-Pierre QUENOT, Esperanza Merino de Lucas, Sheela Godbole, Luis Guillermo Barreto Rocchetti, Katerina Spasovska, William Connors, Kiana Shirani, Umang Agrawal, Srinivas Murthy, Bjorn Blomberg, Vasee Moorthy, Amith Balachandran, Antonio De Pablo Esteban, Mahnaz Amini, Dag Arne Lihaug Hoff, Zeinab Siami, Guillaume Martin-Blondel, Heng Gee Lee, Thrilok Chander Bingi, Vijay Krishnan, ANA BELEN RIVAS PATERNA, Eric D'Ortenzio, Samy Zaky, Carlos Arturo Alvarez-Moreno, Alonso Soto, VIKAS MARWAH, Marco Tulio Medina, Zaira R. Palacios-Baena, Jean-Sébastien Hulot, Miguel Angel Hueda Zavaleta, Felipe García, Francisco Fanjul, Hospices Civils de Lyon (HCL), INSERM UMR-S 606, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, PRES Sorbonne Paris-Cité, and Université Paris Denis Diderot, Université Paris Diderot - Paris 7 (UPD7), Michel-Avella, Amandine, Pan, H., Peto, R., Henao-Restrepo, A. -M., Preziosi, M. -P., Sathiyamoorthy, V., Karim, Q. A., Alejandria, M. M., Garcia, C. H., Kieny, M. -P., Malekzadeh, R., Murthy, S., Srinath Reddy, K., Periago, M. R., Hanna, P. A., Ader, F., Al-Bader, A. M., Alhasawi, A., Allum, E., Alotaibi, A., Alvarez-Moreno, C. A., Appadoo, S., Asiri, A., Aukrust, P., Barratt-Due, A., Bellani, S., Branca, M., Cappel-Porter, H. B. C., Cerrato, N., Chow, T. S., Como, N., Eustace, J., Garcia, P. J., Godbole, S., Gotuzzo, E., Griskevicius, L., Hamra, R., Hassan, M., Hassany, M., Hutton, D., Irmansyah, I., Jancoriene, L., Kirwan, J., Kumar, S., Lennon, P., Lopardo, G., Lydon, P., Magrini, N., Maguire, T., Manevska, S., Manuel, O., Mcginty, S., Medina, M. T., Mesa Rubio, M. L., Miranda-Montoya, M. C., Nel, J., Nunes, E. P., Perola, M., Portoles, A., Rasmin, M. R., Raza, A., Rees, H., Reges, P. P. S., Rogers, C. A., Salami, K., Salvadori, M. I., Sinani, N., Sterne, J. A. C., Stevanovikj, M., Tacconelli, E., Tikkinen, K. A. O., Trelle, S., Zaid, H., Rottingen, J. -A., Swaminathan S., &amp, Luzzati, R, Di Bella, S, Doctoral Programme in Population Health, Doctoral Programme in Biomedicine, HUS Abdominal Center, Department of Surgery, Urologian yksikkö, South Carelia Social and Health care District Eksote, HUS Heart and Lung Center, Department of Medicine, Clinicum, Department of Obstetrics and Gynecology, HUS Gynecology and Obstetrics, UCL - SSS/IREC/LTAP - Louvain Centre for Toxicology and Applied Pharmacology, and UCL - (SLuc) Service de médecine interne générale

Subjects
Male, Kaplan Meier method, Intention to Treat Analysi, MESH: Treatment Failure, MESH: Hydroxychloroquine, remdesivir, Rate ratio, MESH: Intention to Treat Analysis, MESH: Length of Stay, law.invention, Lopinavir/*therapeutic use, 0302 clinical medicine, middle aged, Medicine, Hospital Mortality, MESH: Respiration, Artificial, Antiviral Agents/administration & dosage/adverse effects/*therapeutic use, comparative study, beta1a interferon, MESH: Middle Aged, Alanine, Respiration, adult, clinical trial, General Medicine, 3. Good health, Intention to Treat Analysis, [SDV] Life Sciences [q-bio], aged, health care quality, priority journal, drug withdrawal, Artificial, Interferon, Drug Therapy, Combination, medicine.medical_specialty, Initiation of ventilation, Interferon beta-1a/*therapeutic use, World Health Organization, Antiviral Agents, Article, Duration of hospital stay, antiviral drugs, 03 medical and health sciences, Drug Therapy, death, Humans, MESH: Hospital Mortality, human, MESH: Kaplan-Meier Estimate, Aged, MESH: Humans, treatment duration, extracorporeal oxygenation, Hydroxychloroquine, Length of Stay, major clinical study, mortality, Respiration, Artificial, Adenosine Monophosphate/*analogs & derivatives/therapeutic use, multicenter study, Alanine/*analogs & derivatives/therapeutic use, MESH: Interferon beta-1a, randomized controlled trial, MESH: Female, antivirus agent, [SDV]Life Sciences [q-bio], MESH: Hospitalization, Kaplan-Meier Estimate, 030204 cardiovascular system & hematology, Lopinavir, Adenosine Monophosphate, COVID-19, Female, Hospitalization, Interferon beta-1a, Middle Aged, Treatment Failure, Randomized controlled trial, Interquartile range, law, MESH: COVID-19, MESH: Adenosine Monophosphate, 030212 general & internal medicine, antiviral drugs, Covid-19, MESH: Aged, Hydroxychloroquine/*therapeutic use, MESH: Lopinavir, Covid19, artificial ventilation, drug therapy, ritonavir, hospital patient, female, Combination, medicine.drug, MESH: Antiviral Agents, combination drug therapy, COVID-19/*drug therapy/mortality, Randomization, MESH: Alanine, drug repositioning, drug clearance, adenosine phosphate, coronavirus disease 2019, length of stay, Internal medicine, controlled study, Antiviral Agent, Intention-to-treat analysis, business.industry, MESH: Male, COVID-19 Drug Treatment, purl.org/pe-repo/ocde/ford#3.02.00 [https], MESH: Drug Therapy, Combination, 3121 General medicine, internal medicine and other clinical medicine, business
Abstract

The authors report interim results of the WHO Solidarity trial of four repurposed antiviral drugs - remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a - in patients hospitalized with Covid-19. Effects on overall mortality, initiation of ventilation, and duration of hospital stay are compared. Background World Health Organization expert groups recommended mortality trials of four repurposed antiviral drugs - remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a - in patients hospitalized with coronavirus disease 2019 (Covid-19). Methods We randomly assigned inpatients with Covid-19 equally between one of the trial drug regimens that was locally available and open control (up to five options, four active and the local standard of care). The intention-to-treat primary analyses examined in-hospital mortality in the four pairwise comparisons of each trial drug and its control (drug available but patient assigned to the same care without that drug). Rate ratios for death were calculated with stratification according to age and status regarding mechanical ventilation at trial entry. Results At 405 hospitals in 30 countries, 11,330 adults underwent randomization; 2750 were assigned to receive remdesivir, 954 to hydroxychloroquine, 1411 to lopinavir (without interferon), 2063 to interferon (including 651 to interferon plus lopinavir), and 4088 to no trial drug. Adherence was 94 to 96% midway through treatment, with 2 to 6% crossover. In total, 1253 deaths were reported (median day of death, day 8; interquartile range, 4 to 14). The Kaplan-Meier 28-day mortality was 11.8% (39.0% if the patient was already receiving ventilation at randomization and 9.5% otherwise). Death occurred in 301 of 2743 patients receiving remdesivir and in 303 of 2708 receiving its control (rate ratio, 0.95; 95% confidence interval [CI], 0.81 to 1.11; P=0.50), in 104 of 947 patients receiving hydroxychloroquine and in 84 of 906 receiving its control (rate ratio, 1.19; 95% CI, 0.89 to 1.59; P=0.23), in 148 of 1399 patients receiving lopinavir and in 146 of 1372 receiving its control (rate ratio, 1.00; 95% CI, 0.79 to 1.25; P=0.97), and in 243 of 2050 patients receiving interferon and in 216 of 2050 receiving its control (rate ratio, 1.16; 95% CI, 0.96 to 1.39; P=0.11). No drug definitely reduced mortality, overall or in any subgroup, or reduced initiation of ventilation or hospitalization duration. Conclusions These remdesivir, hydroxychloroquine, lopinavir, and interferon regimens had little or no effect on hospitalized patients with Covid-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay. (Funded by the World Health Organization; ISRCTN Registry number, ; ClinicalTrials.gov number, .)

Published
2020
Full Text
View/download PDF

5. Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-COV-2/COVID 19 en establecimientos de atención de la salud. Recomendaciones basadas en consenso de expertos e informadas en la evidencia

Author

Guillermo Ortiz, Leonar G Aguiar Martinez, Fredy Orlando Guevara Pulido, Ximena Garcia-Quintero, Carlos Arturo Alvarez-Moreno, and JUAN PABLO ROJAS HERNÁNDEZ

Subjects
0301 basic medicine, 03 medical and health sciences, 0302 clinical medicine, General Computer Science, 030106 microbiology, 030231 tropical medicine
Abstract

La Asociación Colombiana de Infectología (ACIN) y el Instituto de Evaluación de Nuevas Tecnologías de la Salud (IETS) conformó un grupo de trabajo para desarrollarrecomendaciones informadas y basadas en evidencia, por consenso de expertos para la atención, diagnóstico y manejo de casos de Covid 19. Estas guías sondirigidas al personal de salud y buscar dar recomendaciones en los ámbitos de la atención en salud de los casos de Covid-19, en el contexto nacional de Colombia.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results